Headlines about Infinity Pharmaceuticals (NASDAQ:INFI) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.3970249553575 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
INFI has been the subject of several recent analyst reports. Zacks Investment Research lowered Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. ValuEngine upgraded Infinity Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th.
Infinity Pharmaceuticals (INFI) opened at 1.00 on Friday. The company has a 50-day moving average price of $1.35 and a 200 day moving average price of $2.05. Infinity Pharmaceuticals has a 1-year low of $0.84 and a 1-year high of $3.84. The stock’s market cap is $50.69 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.12. During the same period last year, the company earned $1.05 EPS. Equities analysts expect that Infinity Pharmaceuticals will post ($0.89) earnings per share for the current fiscal year.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.